Journal of Clinical Endocrinology & Metabolism, Vol 72, 60-64, Copyright © 1991 by Endocrine Society

ARTICLES

Effect of deslorelin dose in the treatment of central precocious puberty

OH Pescovitz, KM Barnes and GB Cutler Jr
Department of Pediatrics, Indiana University Medical Center, Indianapolis 46202.

Central precocious puberty is effectively treated with long-acting LHRH analogs (LHRHas). Although at least six LHRHas have now been used in children, there have been no studies to determine the least effective dose of any of these analogs. We sought to determine the effect of decreasing an efficacious dose of deslorelin (D-Trp6-Pro9-NEt-LHRH) on basal and LHRH-stimulated gonadotropins, estradiol levels, and the rates of linear growth and skeletal maturation in subjects with central precocious puberty. Twenty-nine children with central precocious puberty were enrolled in a double blinded study. All subjects were treated for the initial 3 months with deslorelin at a dose (4 micrograms/kg.day, sc) known to suppress gonadotropins, linear growth velocity, and the rate of skeletal maturation. After 3 months, the subjects were randomly assigned to receive one of three daily sc doses of deslorelin: 4 micrograms/kg (n = 9), 2 micrograms/kg (n = 11), or 1 micrograms/kg (n = 9). They were treated at this dose in double blinded fashion for 15 months, after which time they resumed therapy at a dose of 4 micrograms/kg.day for an additional year. The children in the three groups did not differ in terms of chronological age, bone age, pretreatment growth rate, or Tanner stage at the onset of therapy. Similarly, there were no differences in the clinical and hormonal responses to the first 3 months of LHRHa therapy (4 micrograms/kg.day). During the 15-month period at the three different doses, the three dose groups could not be distinguished from each other in terms of pubertal stage, linear growth velocity, rate of skeletal maturation, sex steroid levels, mean LH or FSH levels, or peak FSH response to LHRH stimulation or to a dose of deslorelin. In contrast, the peak LH response to LHRH stimulation was highest in children treated with the lowest dose (1 micrograms/kg.day; P less than 0.025, by multiple analysis of variance). In addition, the peak LH response to a dose of deslorelin (the LHRHa test) was higher in children treated with 1 micrograms/kg.day than in those treated with 4 micrograms/kg.day (P less than 0.04). In summary, the LHRHa test is a sensitive means for detecting activation of the hypothalamic-pituitary-gonadal axis, and deslorelin at a dose of 1 micrograms/kg.day results in less gonadotropin suppression than a dose of 4 micrograms/kg.day.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				H. J. Hirsch, D. Gillis, D. Strich, B. Chertin, A. Farkas, T. Lindenberg, H. Gelber, and I. M. Spitz The Histrelin Implant: A Novel Treatment for Central Precocious Puberty Pediatrics, December 1, 2005; 116(6): e798 - e802. [Abstract] [Full Text] [PDF]

				K. O. Klein, J. Baron, K. M. Barnes, O. H. Pescovitz, and G. B. Cutler Jr. Use of an Ultrasensitive Recombinant Cell Bioassay to Determine Estrogen Levels in Girls with Precocious Puberty Treated with a Luteinizing Hormone-Releasing Hormone Agonist J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2387 - 2389. [Abstract] [Full Text]